“…Finally, one radiochemistry study was excluded because it reported data from a single patient using 68 Ga-PSMA-11 versus 68 Ga-CHX-A"-DPTA-PSMA PET/CT, an uncommon PET ligand (Wustemann et al, 2016). An overview of the 37 included papers is shown in Table 1 (31 case series) and Table 2, in which six single cases are presented (Chakraborty et al, 2015b;Lawal et al, 2015;Uprimny et al, 2015;Agarwal et al, 2016;Sasikumar et al, 2016;Soydal et al, 2016). Most of the studies included patients with biochemical recurrence, but some studies included data on staging, whereas, other studies used populations with different stages of prostate cancer.…”